LAVAL, QCand CAMBRIDGE, England, May 9, 2022 /PRNewswire/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, announced that Bruce PrichardChairman and CEO of Liminal BioSciences, is scheduled to present an overview of the company at the following upcoming investor conferences:
- HC Wainwright Global Investment Conference on Tuesday, May 24 at 2:30-3:00 p.m. (EDT).
- Jefferies Healthcare Conference on Thursday, June 9 at 2:00-2:30 p.m. (EDT).
Presentations will be available on the Liminal BioSciences website at https://investors.liminalbiosciences.com/Webcasts. An archived replay of the webcast will be available on the Company’s website for at least 7 days after the live event ends.
About Liminal BioSciences Inc.
Liminal BioSciences is a clinical-stage biopharmaceutical company focused on developing novel, distinctive small molecule therapies for inflammatory, fibrotic and metabolic diseases using our drug discovery platform and a research-driven approach. the data. The Company’s lead small molecule product candidate, fezagepras, has completed a Phase 1 multiple escalating dose clinical trial and the Company plans to conduct a Phase 1a single escalating dose clinical trial to provide comparative data to the support for its development plan. In addition, the Company is also currently developing a selective GPR84 antagonist candidate and a selective OXER1 antagonist candidate. Our GPR84 and OXER1 antagonist programs are currently in the preclinical stage.
Liminal BioSciences is engaged in active business activities in Canada and the UK.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking terms. Statements that are not historical in nature, including the words “anticipate”, “expect”, “suggest”, “plan”, “believe”, “intend”, “estimate”, ” target”, “project”, “should”, “could”, “would”, “could”, “will”, “forecast” and other similar expressions are intended to identify forward-looking statements. Such statements include those relating to objectives, strategies and activities of Liminal BioSciences that involve risks and uncertainties Forward-looking information includes statements regarding, among other things: the advancement of Liminal Biosciences’ product candidates, results of planned clinical trials, analysis of our data clinical trials; the potential development of Liminal Biosciences’ R&D programs; the properties of our drug candidates; the timing or nature of preclinical and clinical trials and potential therapeutic areas they.
These statements are “forward-looking” because they are based on our current expectations about the markets in which we operate and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions prove to be inaccurate. Among the factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, risks associated with: the Company’s ability to develop, manufacture and market with success of product candidates, if any; the impact of the COVID-19 pandemic on the Company’s workforce, business operations, clinical development, regulatory activities and financial and other impacts on the business; the availability of funds and resources to pursue R&D projects, clinical developments, manufacturing operations or commercialization activities; the successful and timely initiation or completion of clinical trials; the ability to take advantage of funding opportunities or business opportunities in the pharmaceutical industry; the Company’s ability to resolve the Nasdaq listing issue and regain compliance with Nasdaq listing rules; the uncertainties generally associated with research and development, clinical trials and related regulatory reviews and approvals; and general changes in economic conditions. A more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to differ materially from our current expectations can be found in the Company’s filings and reports with the Securities and Exchange Commission. United States and Canadian Securities Administrators, including in the Annual Report on Form 20-F for the fiscal year ended December 31, 2021, as well as other filings and reports that Liminal Biosciences may make from time to time. These risks may be magnified by the ongoing COVID-19 pandemic and any related impact on Liminal BioSciences’ business and the global economy. Accordingly, we cannot guarantee that any particular forward-looking statement will occur. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. We undertake no obligation to update the forward-looking statements contained in this press release, even if new information becomes available, as a result of future events or for any other reason, except if applicable laws and regulations of securities require it.
SOURCELiminal BioSciences Inc.